Abstract
In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.
| Original language | English |
|---|---|
| Pages (from-to) | 303-305 |
| Number of pages | 3 |
| Journal | Internal Medicine |
| Volume | 42 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2003 Mar 1 |
Keywords
- Angiogenic growth factors
- Multiple myeloma
- Thalidomide
- Tumor angiogenesis
ASJC Scopus subject areas
- Internal Medicine
Fingerprint
Dive into the research topics of 'Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS